revenu million
valu usd unless otherwis note
view despit rise expect impress beat
cf franchis symdeko uptak strong help expand
market tripl combo ph iii enrol quickli competitor
experienc recent setback see stage set near best-in-class
lt growth margin though share appreci start reflect
optim diversif like becom import add
inflect still see potenti upsid rais
price target
symdeko sale exceed expect grown base strong
rx data drive q-o-q revenu symdeko
sale beat well above-consensu estimate consensu
reflect strong rx trend management acknowledg orkambi
cannib sale vs below-consensu
consensu seen mix new start orkambi
discontinu see signific headroom new start sale
growth encouragingli base volum inventori though
continu work hard avoid potenti season slowdown
kalydeco sale in-lin expect guidanc rais
cf product revenu
tripl combo trial fulli enrol still track complet
file anticip later align kol
feedback studi enrol quickli put
finer point enrol time confirm enrol
file later believ het/min studi
could finish first enabl potenti launch though could
pace behind sourc note
site alreadi complet enrol current model
potenti start contribut consensu
sustain revenu ww year het/min alon
still focus secur reimburs key ex-u market
materi updat front management point uk franc
australia key target discuss continu
reimburs uk public impass price recent
management look meet nh leadership minist
tri find compromis australia wait
releas formal minut pbac determin path forward
minut expect next week see larger
ex-u market import full potenti year cf revenu
price prior trade day market close estimate unless otherwis note
bullish prospect cf tripl combo
come recent data program progress
particularli concern long-term threat franchis
given high bar limit potenti competitor
believ high growth prospect estim
ep compound-annual-growth-rate potenti best-in-class margin confer
scarciti valu though share bake optim
outstand initi data tripl combo set high
bar may difficult surpass believ given
compani strong fundament addit appreci
beyond broader biotech tape like
posit leader high-growth high-margin cf
space led kalydeco orkambi like soon symdeko
high bar potenti futur competitor
risk price pressur competit entrant could
outsiz neg impact out-year revenu next
gen corrector set initi ph iii trial though still
complet derisk safeti difficult improv
upon initi data addit tripl combo result
potenti catalyst progress updat tripl combo ph iii
trial dose-rang updat
pdufa date kalydeco infant orkambi
children eu reimburs updat orkambi
on-going initi ph i/ii studi beta-thalassemia
bloomberg capit market estim upside/downside/target
base case assum probabl success
expans het/min improv persistence/compli
tez/iva introduct tez/iva price blend current
kalydeco orkambi price price target deriv
dcf analysi discount rate
success tripl combo enabl expans het/min cf
patient better expect tez/iva and/or ex-u price
power higher complianc improv would lead
upsid estim upsid scenario potenti
dcf-base valuat would
failur tripl combo emerg competit reduc
long-term market share erod price power would lead
downsid estim downsid scenario
potenti dcf-base valuat would
exhibit potenti mileston pipelin
producteventtimelinekalydecopotenti regulatori approv use infant year pdufa date potenti eu regulatori approv use infant year reimburs franc uk approv children pdufa date initi phase studi infant year symdeko potenti approv studi children cf age updat tripl combo ph addit next-gen phase ii studi neuropath deuter ivacaftor fda addit dose-rang fda feedback ind sickl cell ph i/ii studi beta-thalassemia uk canada fda clinic hold sickl cell fibrosi gate residu function mutationsmarketedorkambicyst fibrosi homozygousmarketedtez/iva symkevi cystic fibrosi ciliari dyskenesiaphas corrector homozyg het/min cf ptsphase corrector homozyg het/min cf ptsphase corrector homozyg het/min cf ptsphase corrector homozyg het/min cf ptsphase spinal cord injuryphas deuter ivacaftor concert pharma cystic fibrosi gate residu function mutationsphas crispr beta-thalassmia sickl cell diseasepreclinicalmilestonesdrug/target exhibit incom statement
thousand except per share tez/iva combo- product revenu revenu product oper expens incom net- pre-tax incom incom attribut non-controlling interest- net incom per share outstand share outstand biotechnolog
price target deriv dcf analysi base busi discount
rate termin growth rate price target support outperform rate
risk rate price target
risk includ lower expect commerci uptak tez/iva price pressur cf
competit emerg safeti issu tripl combo
global biotechnolog compani focus develop
small molecul drug seriou unmet diseas compani previous develop
drug fda approv hiv hep multipl approv drug
includ kalydeco orkambi symdeko treatment variou mutat cystic
fibrosi develop pipelin addit cf drug popul
current drug address addit vertex work build pipelin
beyond cf next year vertex aspir becom fulli integr
biopharmaceut compani discoveri commerci global sale
market commerci infrastructur
